High-performance immunoassays demand precision reagents

Dec 3, 2014 3:24:00 PM

Anti-idiotypic antibodies home in on the true target

keyImmunoassays are only as good as the reagents they build on. Following up on the post ‘Success in the balancing act of ADA analysis‘, we found two new articles that clearly show how fine-tuned antibody reagents can support high performance immunoassays.

 

In Drug Discovery Tutorials, in the October issue of GEN, Amanda Turner at AbD Serotec summarized the challenges of analyzing Anti-Drug Antibodies (ADA). She followed up with a presentation of how anti-idiotypic antibodies can be generated using antibody libraries and phage display, which deliver fully human antibodies with excellent binding specificity, ready to be used in sensitive ADA immunoassays.

 

Read more:

Anti-idiotypic antibodies to monitor immune responses, Amanda Turner, GEN, Oct 1, 2014 (vol 34. No 17)

and

Monitoring antibody immune responses against biotherapeutic drugs

In November, Hossein Salimi-Moosavi and his colleagues at Amgen Inc, USA, published an article that describes their screening strategy to deliver anti-idiotypic antibodies with specificity for unique variable regions. Antibodies were selected based on matrix effects, assay sensitivity, epitope resolution, suitability for measuring free drug, and neutralizing bioactivity. As the authors state, anti-idiotypic antibodies are “ideal tools for quantification of therapeutic antibodies because they provide a critical link between analytical specificity and the functional activity of the drug”.

H. Salimi-Moosavi et al. Multifactorial Screening Strategy to Identify Anti-Idiotypic Reagents for Bioanalytical Support of Antibody Therapeutics, Analytical Biochemistry (2014)

 

You can also learn more about how Gyrolab xP workstation, combined with Gyrolab CDs and dedicated ADA software, provides an efficient way of optimizing Anti-Drug Antibody analysis by downloading the Product Information Sheet ‘Gyrolab ADA Solution’.

 

Download

 

Topics: Assay Development, ADA